In acute myeloid leukemia (AML) with complex aberrant karyotype, a loss of one TP53 allele is frequently observed. We analyzed the incidence of TP53 mutations and deletions in 107 AML with complex aberrant karyotype. In 50 of 57 cases showing a loss of one TP53 allele, a TP53 mutation was detected in the remaining allele. In addition, in 33 of 50 cases with two TP53 copies, a TP53 mutation was found. Therefore, the frequency of TP53 mutations in AML with complex aberrant karyotype was 78%. In a second step, we analyzed TP53 mutations in a cohort of AML comprising different cytogenetic subgroups. TP53 mutations were detected in 33 of 235 cases (14%). Coincidences with other molecular mutations were rare. We confirmed a high incidence of TP53 mutations in AML with a complex aberrant karyotype (29/42, 69%) 
Introduction
The TP53 gene is the most frequently mutated gene in human tumors identified so far. 1 In contrast, the reported TP53 mutation rate in acute myeloid leukemia (AML) is low. [2] [3] [4] [5] However, in AML with complex aberrant karyotype, a loss of the short arm of chromosome 17 is frequently observed, where the TP53 gene is located. 6 In a previous series, we showed a loss of one copy of the TP53 gene in 66 of 125 cases with AML and a complex aberrant karyotype (52.8%) by fluorescence in situ hybridization (FISH). 7 According to the classical tumor suppressor gene model, it can be assumed that mutations in the remaining allele are frequent. Therefore, the aim of this study was to determine the frequency of TP53 deletions and mutations in AML with a complex aberrant karyotype. In addition, we evaluated a cohort of AML representing all frequent cytogenetic subgroups for their respective frequency of TP53 mutations and analyzed the relation to other molecular genetic aberrations.
Patients and methods

Patients
After the informed written consent was obtained, bone marrow or peripheral blood samples, which were referred to our laboratory were analyzed with chromosome banding analysis, interphase FISH and for molecular mutations. Two different cohorts were analyzed: (1) 107 cases with AML and a complex aberrant karyotype defined as showing three or more clonal abnormalities but no balanced rearrangement leading to a leukemia-specific fusion gene; (2) 235 AML cases (214 de novo AML, 13 therapy-related AML (t-AML) and eight AML evolving from a myelodysplastic syndrome (s-AML)) comprising cases of all frequent cytogenetic categories ( Table 1) .
Metaphase cytogenetics
Cultivation and chromosome preparation was carried out as described elsewhere. In each case with a complex aberrant karyotype, results of G-banding analysis were confirmed by 24-color FISH. Chromosomes were classified according to the International System for Human Cytogenetic Nomenclature (ISCN, 1995). 8 
Fluorescence in situ hybridization
Interphase FISH with a probe for the TP53 gene (ABBOTT, Wiesbaden, Germany) was performed in all cases with a complex aberrant karyotype as described previously.
7
TP53 mutation analysis TP53 mutation analysis was carried out using the Affymetrix p53 GeneChip assay, denaturating high performance liquid chromatography and direct sequencing. Exons 3-4, 5-6, 7 and 8-9 of the TP53 gene were amplified by PCR from genomic DNA (200 ng) and subsequently analyzed by denaturating high performance liquid chromatography on the WAVE-system (Transgenomic Inc., Omaha, Nebraska, USA). Aberrant amplicons were verified by direct sequencing in both orientations using Big Dye Chemistry (Applied Biosystems, Weiterstadt, Germany) and analyzed on a 3130 Genetic Analyzer (Applied Biosystems). In all 24 cases without a TP53 mutation observed by the Affymetrix p53 GeneChip assay or denaturating high performance liquid chromatography in the first cohort of 107 cases with a complex aberrant karyotype, direct sequencing of exon 3-9 and intron 2-9 was carried out.
Mutations analysis within FLT3, NPM1 and MLL Fms-related tyrosine kinase 3 (FLT3) length mutation, mixedlineage leukemia (MLL) partial tandem duplication and nucleophosmin (NPM1) mutation analysis was performed as published elsewhere. All cases in cohort 2 were analyzed for all three mutations.
Results and discussion
The first cohort analyzed comprised 107 AML cases with a complex aberrant karyotype. TP53 deletions were detected by interphase FISH in 57 cases, while 50 cases showed two copies of TP53 in FISH analysis. TP53 mutations were detected in 50 of 57 cases showing a loss of one TP53 allele (88%). In addition, 33 cases (66%) without a TP53 loss showed a TP53 mutation. Therefore, the overall frequency of TP53 mutations was 78% in AML with complex aberrant karyotype. In total, 90 mutations were detected in 83 cases. Two mutations within the TP53 gene were found in four cases with two TP53 copies and in three cases with loss of one TP53 allele. Overall, only 17 of 107 cases (16%) showed neither loss nor mutation of TP53. The type of TP53 mutation detected in 107 cases with AML and complex aberrant karyotype is depicted in Table 1 .
In cohort 2 comprising 235 AML cases, TP53 mutations were detected in 33 of the 235 cases (29 de novo AML, two t-AML, and two s-AML) (14%). FLT3-LM was observed in 33 (14%), MLL-PTD in eight (3.4%), NPM1 mutations in 43 cases (18.3%), respectively. In one case each, a TP53 mutation occurred in combination with an FLT3-LM or MLL-PTD, respectively. A TP53 mutation was not detected together with an NPM1 mutation. Suzuki et al. 9 reported on two cases carrying both a TP53 and an NPM1 mutation out of 60 cases with NPM1 mutation (3.3%).
A complex aberrant karyotype was present in 29 of 33 cases (87.9%) with a TP53 mutation. The remaining four cases with TP53 mutation showed a normal karyotype, a trisomy 8, trisomy 13 and t(8;21), each aberration occurring as the sole abnormality, respectively. Therefore, we confirmed a high incidence of TP53 mutations in AML with complex aberrant karyotype (29/ 42, 69%). On the other hand, TP53 mutations are very rare in AML without a complex aberrant karyotype (4/193, 2.1%).
The frequency and association between TP53 mutations and karyotype, FLT3 length mutations, NPM1 mutations and partial tandem duplications within the MLL gene in cohort 2 (n ¼ 235) are shown in Table 2 . A close association was observed between TP53 mutations and a complex aberrant karyotype, while TP53 mutations were nonrecurrent in all other cytogenetic subgroups. In addition, TP53 mutations occurred only rarely in combination with FLT3 length mutations and partial tandem duplications of the MLL gene and were not observed together with NPM1 mutations, which are strongly associated with AML and normal karyotype. Therefore, a close correlation of cytogenetic abnormalities and molecular mutations is confirmed.
Furthermore, we divided AML with complex aberrant karyotype into two subgroups: (1) AML with 'typical' complex aberrant karyotype showing a deletion of at least one of the following regions: 5q31, 7q31, 17p13 as previously proposed and (2) AML with 'untypical' complex aberrant karyotype comprising all others. 7 The frequency of TP53 mutations within the typical complex aberrant karyotype group was 76.0% (20/ 26), while in the untypical group, it was 56.2% (9/16; P ¼ 0.16).
In therapy-related myelodysplastic syndrome (MDS) and AML, an association between 5q deletions, a complex aberrant karyotype and TP53 mutations were reported. 10, 11 In our series in both cases with 5q deletion as the sole abnormality, no TP53 mutation was observed. In AML with a complex aberrant karyoytpe showing a 5q deletion, the TP53 mutations rate was 76% (19/25) as compared to 58.8% (10/17) in cases with complex aberrant karyotype without 5q deletion (P ¼ 0.237).
Conclusions
In conclusion, in AML, TP53 mutations are highly associated with AML and complex aberrant karyotype and occur very infrequently in all other cytogenetic subgroups (Po0.001). They occur frequently, in particular, in the subgroup showing a typical pattern of chromosomal deletions (5q, 7q and 17p). TP53 mutations might explain in part the poor prognosis due to chemoresistance of AML with complex aberrant karyotype, which has been observed consistently in clinical trials. [12] [13] [14] [15] [16] In addition to cytogenetics, a rapid diagnostic screening for TP53 mutations could be a valuable tool to identify a subgroup of AML with poor prognosis. This would allow the early assignment of patients to alternative treatment strategies using options targeting the TP53 pathway. Table 1 Type of TP53 mutation detected in 107 cases with AML and complex aberrant karyotype (cohort 1)
Total
Cases with the loss of one TP53 copy Cases with two TP53 copies 73  46  27  Nonsense mutation  6  3  3  Deletion  2  0  2  Insertion  2  2  0  Splice site mutation  7  2  5  90  53  37 Abbreviation: AML, acute myeloid leukemia. 
Missense mutation
